Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Leukemia, Lymphoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Long-term follow-up of 30 patients with ALL in remission for at least 10 years has demonstrated ten cases of secondary malignancies. Of 31 long-term female survivors of ALL or AML younger than 40 years, 26 resumed normal menstruation following completion of therapy. Among 36 live offspring of survivors, two congenital problems occurred.[14]
Sources: 14
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Successful treatment of acute lymphoblastic leukemia (ALL) consists of the control of bone marrow and systemic disease and the treatment (or prevention) of sanctuary-site disease, particularly the central nervous system (CNS).[1,2] The cornerstone of this strategy includes systemically administered combination chemotherapy with CNS preventive therapy. CNS prophylaxis is achieved with chemotherapy (intrathecal and/or high-dose systemic therapy) and, in some cases, cranial radiation therapy.
Treatment is divided into three phases:
Remission induction.
CNS prophylaxis.
Consolidation (also called remission continuation or maintenance).
The average length of treatment for ALL ranges from 1.5 to 3 years in the effort to eradicate the leukemic cell population. Younger adults with ALL may be eligible for selected clinical trials for childhood ALL. For more information, see the Adolescents and Young Adults With ALL section in Childhood Acute Lymphoblastic Leukemia Treatment.
Entry into a clinical trial is highly desirable to ensure adequate patient treatment and maximal information retrieval from the treatment of this highly responsive, but usually fatal, disease.
| Disease Status | Treatment Options |
|---|---|
| BMT = bone marrow transplant; CNS = central nervous system. | |
| Untreated ALL | Remission induction therapy |
| CNS prophylaxis therapy | |
| ALL in remission | Consolidation therapy |
| CNS prophylaxis therapy | |
| Recurrent ALL | Reinduction chemotherapy followed by allogeneic BMT |
| Blinatumomab followed by allogeneic BMT | |
| Inotuzumab ozogamicin followed by allogeneic BMT | |
| Palliative radiation therapy | |
| Dasatinib | |
| Revumenib | |
Sources: Disease Status · Remission induction therapy · CNS prophylaxis therapy · Consolidation therapy · CNS prophylaxis therapy · Reinduction chemotherapy · Blinatumomab · Inotuzumab ozogamicin · Palliative radiation therapy · Dasatinib · Revumenib
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Treatment options for untreated acute lymphoblastic leukemia (ALL) include:
Remission induction therapy, including:
Sources: Remission induction therapy
Remission induction therapy, including:
Combination chemotherapy.
Imatinib mesylate (for patients with Philadelphia chromosome [Ph]–positive ALL).
Imatinib mesylate combined with combination chemotherapy (for patients with Ph-positive ALL).
Supportive care.
Central nervous system (CNS) prophylaxis therapy, including:
Central nervous system (CNS) prophylaxis therapy, including:
Cranial radiation therapy plus intrathecal (IT) methotrexate.
High-dose systemic methotrexate and IT methotrexate without cranial radiation therapy.
IT chemotherapy alone.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Sixty percent to 80% of adults with ALL usually achieve a complete remission after appropriate induction therapy. Appropriate initial treatment, usually consisting of a regimen that includes the combination of vincristine, prednisone, and an anthracycline, with or without asparaginase, results in a complete response rate of up to 80%. In patients with Ph-positive ALL, the remission rate is generally greater than 90% when standard induction regimens are combined with BCR::ABL1 tyrosine kinase inhibitors. In the largest study published to date of Ph-positive ALL patients, 1,913 adult patients with ALL had a 5-year overall survival (OS) rate of 39%.[1]
Sources: 1
Patients who experience a relapse after remission usually die within 1 year, even if a second complete remission is achieved. If there are appropriate available donors and if the patient is younger than 55 years, bone marrow transplant may be considered.[2] Transplant centers performing five or fewer transplants annually usually have poorer results than larger centers.[3] If allogeneic transplant is considered, it is recommended to avoid transfusions with blood products from a potential donor.[4-10]
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline. Some regimens, including those used in a Cancer and Leukemia Group B (CALGB) study (CLB-8811), also add other drugs, such as asparaginase or cyclophosphamide. Current multiagent induction regimens result in complete response rates that range from 60% to 90%.[1,4,5,11,12]
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Imatinib mesylate is often incorporated into the therapeutic plan for patients with Ph-positive ALL. Imatinib mesylate, an orally available inhibitor of the BCR::ABL1 tyrosine kinase, has shown clinical activity as a single agent in Ph-positive ALL.[13,14][Level of evidence C3] More commonly, particularly in younger patients, imatinib is incorporated into combination chemotherapy regimens. There are several published single-arm studies in which the complete response rate and survival rate are compared with historical controls.
Sources: 13 · 14 · Level of evidence C3
Evidence (imatinib mesylate):
Several studies have suggested that the addition of imatinib to conventional combination chemotherapy induction regimens results in complete response rates, event-free survival rates, and OS rates that are higher than those in historical controls.[15-17] At the present time, no conclusions can be drawn regarding the optimal imatinib dose or schedule.
In a study of imatinib combined with chemotherapy from the Northern Italy Leukemia Group, patients with newly diagnosed, untreated Ph-positive ALL were treated with an induction regimen containing idarubicin, vincristine, prednisone, and L-asparaginase.[18] After accrual of an initial cohort, the study was modified to include the use of imatinib (600 mg qd from days 15 to 21). In consolidation, patients received imatinib (600 mg qd for 7 days) beginning 3 days before the start of each course of chemotherapy.
Sources: 18
In a study of imatinib combined with chemotherapy from the Northern Italy Leukemia Group, patients with newly diagnosed, untreated Ph-positive ALL were treated with an induction regimen containing idarubicin, vincristine, prednisone, and L-asparaginase.[18] After accrual of an initial cohort, the study was modified to include the use of imatinib (600 mg qd from days 15 to 21). In consolidation, patients received imatinib (600 mg qd for 7 days) beginning 3 days before the start of each course of chemotherapy.
For all patients who achieved remission, the intent was to proceed to allogeneic transplant when and if an HLA-matched donor could be identified. Patients lacking a donor received an autologous transplant. After completion of chemotherapy and transplant, all patients were to receive maintenance imatinib for as long as tolerated. After 20 patients had accrued to the imatinib arm, L-asparaginase was omitted from the induction regimen from both arms because of toxicity.
Outcomes for the first cohort of 35 patients who did not receive imatinib were compared with those of the subsequent cohort of 59 imatinib-treated patients. For patients treated with imatinib, the OS probability was 38% at 5 years (median, 3.1 years) versus 23% in the imatinib-free group (median, 1.1 year; P = .009).[18][Level of evidence C1]
Sources: 18 · Level of evidence C1
The drawbacks of this nonrandomized study were the small sample size (94 total patients) and the change in the treatment regimen (omission of L-asparaginase) midway through the study. However, the results suggested that inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage.
In another study, ten patients with Ph-positive ALL and ten patients with chronic myeloid leukemia in lymphoid blast crisis were treated with doses of imatinib ranging from 300 mg to 1,000 mg per day.[13]
Sources: 13
In another study, ten patients with Ph-positive ALL and ten patients with chronic myeloid leukemia in lymphoid blast crisis were treated with doses of imatinib ranging from 300 mg to 1,000 mg per day.[13]
Of these 20 patients, four had complete hematologic remission and ten had marrow responses.
Responses were short lived, with most of these patients experiencing disease relapse at a median of 58 days after the start of therapy.
In another study, 48 patients with Ph-positive ALL were treated with 400 mg to 800 mg of imatinib per day.[14]
Sources: 14
In another study, 48 patients with Ph-positive ALL were treated with 400 mg to 800 mg of imatinib per day.[14]
The overall response rate was 60%, with 9 out of 48 patients (19%) achieving a complete remission.
The responses again were short, with a median duration of 2.2 months.
In each of these studies, common toxicities were nausea and liver enzyme abnormalities, which necessitated interruption and/or dose reduction of imatinib.[13,14] Subsequent allogeneic transplant does not appear to be adversely affected by the addition of imatinib to the treatment regimen. For more information, see Nausea and Vomiting Related to Cancer Treatment.
Sources: 13 · 14 · Nausea and Vomiting Related to Cancer Treatment
Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials. If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Since myelosuppression is an anticipated consequence of both leukemia and its treatment with chemotherapy, patients must be closely monitored during remission induction treatment. Facilities must be available for hematologic support and for the treatment of infectious complications.
Supportive care during remission induction treatment should routinely include red blood cell and platelet transfusions, when appropriate.[19,20]
Evidence (supportive care):
Randomized clinical trials have shown similar outcomes for patients who received prophylactic platelet transfusions at a level of 10,000/mm3 rather than at a level of 20,000/mm3.[21]
Sources: 21
The incidence of platelet alloimmunization was similar among groups randomly assigned to receive one of the following from random donors:[22]
Sources: 22
The incidence of platelet alloimmunization was similar among groups randomly assigned to receive one of the following from random donors:[22]
Pooled platelet concentrates.
Filtered, pooled platelet concentrates.
Ultraviolet B-irradiated, pooled platelet concentrates.
Filtered platelets obtained by apheresis.
Empiric broad-spectrum antimicrobial therapy is an absolute necessity for febrile patients who are profoundly neutropenic.[23,24] Careful instruction in personal hygiene and dental care and in recognizing early signs of infection are appropriate for all patients. Elaborate isolation facilities, including filtered air, sterile food, and gut flora sterilization, are not routinely indicated but may benefit patients undergoing transplants.[25,26]
Rapid marrow ablation with consequent earlier marrow regeneration decreases morbidity and mortality. White blood cell transfusions can be beneficial in selected patients with aplastic marrow and serious infections that are not responding to antibiotics.[27] Prophylactic oral antibiotics may be appropriate in patients with expected prolonged, profound granulocytopenia (<100/mm3 for 2 weeks), although further studies are necessary.[28] Serial surveillance cultures may be helpful in detecting the presence or acquisition of resistant organisms in these patients.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
The early institution of CNS prophylaxis is critical to achieve control of sanctuary disease.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Two additional subtypes of ALL require special consideration. B-cell ALL, which expresses surface immunoglobulin and cytogenetic abnormalities such as t(8;14), t(2;8), and t(8;22), is not usually cured with typical ALL regimens. Aggressive, brief-duration, high-intensity regimens, including those previously used in CLB-9251 (NCT00002494), that are similar to those used in aggressive non-Hodgkin lymphoma have shown high response rates and cure rates (75% complete response rate; 40% failure-free survival rate).[31-33] Similarly, T-cell ALL, including lymphoblastic lymphoma, has shown high cure rates when treated with cyclophosphamide-containing regimens.[4]
Whenever possible, patients with B-cell or T-cell ALL should enroll in clinical trials designed to improve the outcomes in these subsets.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Treatment options for acute lymphoblastic leukemia (ALL) in remission include:
Consolidation therapy, including:
Sources: Consolidation therapy
Consolidation therapy, including:
Chemotherapy.
Ongoing treatment with a BCR::ABL1 tyrosine kinase inhibitor, such as imatinib, nilotinib, or dasatinib.
Autologous or allogeneic bone marrow transplant (BMT).
Central nervous system (CNS) prophylaxis therapy, including:
Central nervous system (CNS) prophylaxis therapy, including:
Cranial radiation therapy plus intrathecal (IT) methotrexate.
High-dose systemic methotrexate and IT methotrexate without cranial radiation therapy.
IT chemotherapy alone.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Current approaches to consolidation therapy for ALL include short-term, relatively intensive chemotherapy followed by:
Longer-term therapy at lower doses (maintenance therapy).
Allogeneic BMT.
Because the optimal consolidation therapy for patients with ALL is still unclear, patients should consider participating in clinical trials. For more information, see the Treatment of Diffuse Small Noncleaved-Cell/Burkitt Lymphoma section in Aggressive B-Cell Non-Hodgkin Lymphoma Treatment.
Sources: Treatment of Diffuse Small Noncleaved-Cell/Burkitt Lymphoma
Evidence (chemotherapy):
Several trials, including studies from the Cancer and Leukemia Group B (CLB-8811) and the completed European Cooperative Oncology Group (ECOG-2993 [NCT00002514]), of aggressive consolidation chemotherapy for ALL have confirmed a long-term disease-free survival (DFS) rate of approximately 40%.[1-7]
Several trials, including studies from the Cancer and Leukemia Group B (CLB-8811) and the completed European Cooperative Oncology Group (ECOG-2993 [NCT00002514]), of aggressive consolidation chemotherapy for ALL have confirmed a long-term disease-free survival (DFS) rate of approximately 40%.[1-7]
In two series,[4,5] especially good prognoses were found for patients with T-cell lineage ALL, with DFS rates of 50% to 70% for patients receiving consolidation therapy.
These series represent a significant improvement in DFS rates over previous, less intensive chemotherapeutic approaches.
In contrast, poor cure rates were demonstrated in patients with Philadelphia chromosome (Ph)–positive ALL, B-cell lineage ALL with an L3 phenotype (surface immunoglobulin positive), and B-cell lineage ALL characterized by t(4;11).
Administration of the newer dose-intensive schedules can be difficult and should be performed by physicians experienced in these regimens at centers equipped to deal with potential complications. In studies that eliminated continuation or maintenance chemotherapy, patients had outcomes inferior to those of patients in studies with extended treatment durations.[8,9] Imatinib has been incorporated into maintenance regimens in patients with Ph-positive ALL.[10-12]
Evidence (allogeneic and autologous BMT):
Allogeneic BMT results in the lowest incidence of leukemic relapse, even when compared with a BMT from an identical twin (syngeneic BMT). This finding has led to the concept of an immunologic graft-versus-leukemia effect similar to graft-versus-host disease (GVHD). The improvement in DFS in patients undergoing allogeneic BMT as primary consolidation therapy is offset, in part, by the increased morbidity and mortality from GVHD, veno-occlusive disease of the liver, and interstitial pneumonitis.[13]
Sources: 13
The results of a series of retrospective and prospective studies published between 1987 and 1994 suggest that allogeneic BMT or autologous BMT as consolidation therapy offer no survival advantage over intensive chemotherapy, except perhaps for patients with high-risk or Ph-positive ALL.[14-17] This was confirmed in the ECOG-2993 study (NCT01505699).[7]
The results of a series of retrospective and prospective studies published between 1987 and 1994 suggest that allogeneic BMT or autologous BMT as consolidation therapy offer no survival advantage over intensive chemotherapy, except perhaps for patients with high-risk or Ph-positive ALL.[14-17] This was confirmed in the ECOG-2993 study (NCT01505699).[7]
The use of allogeneic BMT as primary consolidation therapy is limited by both the need for an HLA-matched sibling donor and the increased mortality from allogeneic BMT in patients in their fifth or sixth decade.
The mortality from allogeneic BMT using an HLA-matched sibling donor in these studies ranged from 20% to 40%.
Following on the results of earlier studies, the International ALL Trial (ECOG-2993) was launched to examine the role of transplant as consolidation therapy for ALL more definitively. Patients were accrued from 1993 to 2006.[7] Patients with Ph-negative ALL between the ages of 15 years and 59 years received identical multiagent induction therapy resembling previously published regimens.[1-3] Patients in remission were then eligible for HLA typing; patients with a fully matched sibling donor underwent allogeneic BMT as consolidation therapy. Patients without a donor were randomly assigned to receive either an autologous BMT or maintenance chemotherapy. The primary outcome measured was overall survival (OS). Event-free survival, relapse rate, and nonrelapse mortality were secondary outcomes. A total of 1,929 patients were registered and stratified according to age, white blood cell (WBC) count, and time to remission. High-risk patients were defined as those having a high WBC count at presentation or those older than 35 years.
Following on the results of earlier studies, the International ALL Trial (ECOG-2993) was launched to examine the role of transplant as consolidation therapy for ALL more definitively. Patients were accrued from 1993 to 2006.[7] Patients with Ph-negative ALL between the ages of 15 years and 59 years received identical multiagent induction therapy resembling previously published regimens.[1-3] Patients in remission were then eligible for HLA typing; patients with a fully matched sibling donor underwent allogeneic BMT as consolidation therapy. Patients without a donor were randomly assigned to receive either an autologous BMT or maintenance chemotherapy. The primary outcome measured was overall survival (OS). Event-free survival, relapse rate, and nonrelapse mortality were secondary outcomes. A total of 1,929 patients were registered and stratified according to age, white blood cell (WBC) count, and time to remission. High-risk patients were defined as those having a high WBC count at presentation or those older than 35 years.
Ninety percent of patients in this study achieved remission after induction therapy. Of these patients, 443 had an HLA-identical sibling, 310 of whom underwent an allogeneic BMT. For the 456 patients in remission who were eligible for transplant but lacked a donor, 227 received chemotherapy alone, while 229 underwent an autologous BMT.
By donor-to-no-donor analysis, standard-risk ALL patients with an HLA-identical sibling had a 5-year OS rate of 53%, compared with 45% for patients lacking a donor (P = .01).
In a subgroup analysis, the advantage for patients with standard-risk ALL who had donors remained significant (OS rate, 62% vs. 52%; P = .02).
Following on the results of earlier studies, the International ALL Trial (ECOG-2993) was launched to examine the role of transplant as consolidation therapy for ALL more definitively. Patients were accrued from 1993 to 2006.[7] Patients with Ph-negative ALL between the ages of 15 years and 59 years received identical multiagent induction therapy resembling previously published regimens.[1-3] Patients in remission were then eligible for HLA typing; patients with a fully matched sibling donor underwent allogeneic BMT as consolidation therapy. Patients without a donor were randomly assigned to receive either an autologous BMT or maintenance chemotherapy. The primary outcome measured was overall survival (OS). Event-free survival, relapse rate, and nonrelapse mortality were secondary outcomes. A total of 1,929 patients were registered and stratified according to age, white blood cell (WBC) count, and time to remission. High-risk patients were defined as those having a high WBC count at presentation or those older than 35 years. › In a subgroup analysis, the advantage for patients with standard-risk ALL who had donors remained significant (OS rate, 62% vs. 52%; P = .02).
For patients with high-risk disease (older than 35 years or high WBC count), the difference in OS was 41% versus 35% (donor vs. no donor) but was not significant (P = .2).
Relapse rates were significantly lower (P < .00005) for both standard- and high-risk patients with HLA-matched donors.
Following on the results of earlier studies, the International ALL Trial (ECOG-2993) was launched to examine the role of transplant as consolidation therapy for ALL more definitively. Patients were accrued from 1993 to 2006.[7] Patients with Ph-negative ALL between the ages of 15 years and 59 years received identical multiagent induction therapy resembling previously published regimens.[1-3] Patients in remission were then eligible for HLA typing; patients with a fully matched sibling donor underwent allogeneic BMT as consolidation therapy. Patients without a donor were randomly assigned to receive either an autologous BMT or maintenance chemotherapy. The primary outcome measured was overall survival (OS). Event-free survival, relapse rate, and nonrelapse mortality were secondary outcomes. A total of 1,929 patients were registered and stratified according to age, white blood cell (WBC) count, and time to remission. High-risk patients were defined as those having a high WBC count at presentation or those older than 35 years.
In contrast to allogeneic BMT, autologous BMT was less effective than maintenance chemotherapy as consolidation treatment (5-year OS rate, 46% for chemotherapy vs. 37% for autologous BMT; P = .03).
The results of this trial suggest the existence of a graft-versus-leukemia effect for adult Ph-negative ALL and support the use of sibling donor allogeneic BMT as the consolidation therapy providing the greatest chance for long-term survival for patients with standard-risk adult ALL in first remission.[7][Level of evidence B4]
Sources: 7 · Level of evidence B4
The results also suggest that in the absence of a sibling donor, maintenance chemotherapy is preferable to autologous BMT as consolidation therapy.[7][Level of evidence B4]
Sources: 7 · Level of evidence B4
The use of matched unrelated donors for allogeneic BMT is currently under evaluation. However, because of its current high treatment-related morbidity and mortality, allogeneic BMT is reserved for patients in second remission or beyond. The dose of total-body radiation therapy administered is associated with the incidence of acute and chronic GVHD and may be an independent predictor of leukemia-free survival.[18][Level of evidence C1]
Sources: 18 · Level of evidence C1
Evidence (B-cell ALL):
Aggressive cyclophosphamide-based regimens similar to those used in aggressive non-Hodgkin lymphoma have shown improved outcome of prolonged DFS for patients with B-cell ALL (L3 morphology, surface immunoglobulin positive).[19]
Sources: 19
One group of investigators retrospectively reviewed three sequential cooperative group trials from Germany and found the following results:[19]
Sources: 19
One group of investigators retrospectively reviewed three sequential cooperative group trials from Germany and found the following results:[19]
A marked improvement in survival, from zero survivors in a 1981 study that used standard pediatric therapy and lasted 2.5 years, to a 50% survival rate in two subsequent trials that used rapidly alternating lymphoma-like chemotherapy and were completed within 6 months.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
The early institution of CNS prophylaxis is critical to achieve control of sanctuary disease. Some authors have suggested that there is a subgroup of patients at low risk of CNS relapse for whom CNS prophylaxis may not be necessary. However, this concept has not been tested prospectively.[20]
Sources: 20
Aggressive CNS prophylaxis remains a prominent component of treatment.[19] This report, which requires confirmation in other cooperative group settings, is encouraging for patients with L3 ALL. Patients with surface immunoglobulin and L1 or L2 morphology did not benefit from this regimen. Similarly, patients with L3 morphology and immunophenotype, but unusual cytogenetic features, were not cured with this approach. A WBC count of less than 50,000 per microliter predicted improved leukemia-free survival in a univariate analysis.
Sources: 19
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Treatment options for recurrent acute lymphoblastic leukemia (ALL) include:
Reinduction chemotherapy followed by allogeneic bone marrow transplant (BMT).
Sources: Reinduction chemotherapy
Blinatumomab followed by allogeneic BMT.
Sources: Blinatumomab
Inotuzumab ozogamicin followed by allogeneic BMT.
Sources: Inotuzumab ozogamicin
Palliative radiation therapy (for patients with symptomatic recurrence).
Sources: Palliative radiation therapy
Dasatinib (for patients with Philadelphia chromosome [Ph]–positive ALL).
Sources: Dasatinib
Revumenib.
Sources: Revumenib
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Autologous transplant.
Immunomodulation.
Chimeric antigen receptor (CAR) T-cell therapy.[8]
Sources: 8
Novel chemotherapeutic or biological agents.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Patients with ALL who experience a relapse after chemotherapy and maintenance therapy are unlikely to be cured by further chemotherapy alone. These patients should be considered for reinduction chemotherapy followed by allogeneic BMT.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Blinatumomab is a bispecific antibody targeting CD19 and CD3. The U.S. Food and Drug Administration (FDA) has approved blinatumomab for use in patients with relapsed or refractory B-cell ALL.
Evidence (blinatumomab):
A randomized phase III study of blinatumomab versus one of four standard reinduction regimens was conducted in patients with primary refractory disease, which was refractory to salvage, with a first relapse lasting fewer than 12 months, a second or greater relapse, or any relapse after allogeneic transplant.[9] The four regimens included the following: fludarabine, high-dose cytosine arabinoside, and granulocyte colony-stimulating factor with or without anthracycline; a high-dose cytosine arabinoside–based regimen; a high-dose methotrexate-based regimen; or a clofarabine-based regimen.
Sources: 9
A randomized phase III study of blinatumomab versus one of four standard reinduction regimens was conducted in patients with primary refractory disease, which was refractory to salvage, with a first relapse lasting fewer than 12 months, a second or greater relapse, or any relapse after allogeneic transplant.[9] The four regimens included the following: fludarabine, high-dose cytosine arabinoside, and granulocyte colony-stimulating factor with or without anthracycline; a high-dose cytosine arabinoside–based regimen; a high-dose methotrexate-based regimen; or a clofarabine-based regimen.
Remission rates were 43.9% for the blinatumomab-treated group versus 24.6% in the standard-treatment group (odds ratio, 2.40; 95% confidence interval [CI], 1.51–3.80).
Overall survival (OS) was superior in the blinatumomab-treated group (7.7 months vs. 4.0 months in the standard-treatment group), with a hazard ratio (HR) of .71 (95% CI, 0.55–0.93), favoring blinatumomab.
Adverse events occurred at similar rates in both groups, and the only unique side effect of blinatumomab was cytokine-release syndrome, which was seen in 4.9% of patients.
Blinatumomab should be considered as an option for reinduction therapy for patients with primary refractory disease, which is refractory to salvage, with a first relapse lasting fewer than 12 months, a second or greater relapse, or any relapse after allogeneic transplant.[9][Level of evidence A1]
Sources: 9 · Level of evidence A1
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Inotuzumab ozogamicin is an antibody-drug conjugate targeting CD22, which contains a conjugated toxin, calicheamicin. The FDA has approved inotuzumab ozogamicin for use in patients with relapsed or refractory B-cell ALL with CD22 expression.
Evidence (inotuzumab ozogamicin):
A randomized phase III study compared inotuzumab ozogamicin with one of three standard reinduction regimens. The trial enrolled 218 patients, aged 18 years or older, who had relapsed or refractory disease and were to receive their first or second salvage regimen.[10] The three standard regimens consisted of fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG), cytarabine and mitoxantrone, or high-dose cytarabine.
Sources: 10
A randomized phase III study compared inotuzumab ozogamicin with one of three standard reinduction regimens. The trial enrolled 218 patients, aged 18 years or older, who had relapsed or refractory disease and were to receive their first or second salvage regimen.[10] The three standard regimens consisted of fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG), cytarabine and mitoxantrone, or high-dose cytarabine.
Complete remission or complete remission with incomplete count recovery rates were 80.7% (95% CI, 72.1%–87.7%) in the inotuzumab group versus 29.4% (95% CI, 21.0%–38.8%) in the standard-treatment group (P < .001).
Progression-free survival was superior in the inotuzumab-treated group (5.0 months vs. 1.8 months in the standard-treatment group) with an HR of 0.45 (97.5 CI, 0.34–0.61; P < .001).
Duration of remission was short in both groups; duration in the inotuzumab group was 4.6 months (95% CI, 3.9–5.4) and duration in the standard chemotherapy group was 3.1 months (95% CI, 1.4–4.9).
Of the 48 patients in the inotuzumab arm who proceeded to transplant after therapy, 10 developed veno-occlusive disease. Of the 20 patients who proceeded to transplant after remission on the standard chemotherapy arm, 1 developed veno-occlusive disease.
OS was not statistically prolonged in the inotuzumab group (7.7 months in the inotuzumab group vs. 6.7 months in the standard-treatment group) (HR, 0.77; 97.5% CI, 0.58–1.03; P = .04) because of a failure to meet a study-prespecified boundary of P = .0208.
Grade 3 or higher adverse events were more common in the inotuzumab group. Veno-occlusive disease of the liver occurred in 11% of patients in the inotuzumab group and 1% of patients in the standard-treatment group.
Inotuzumab ozogamicin may be an option for reinduction for patients with relapsed or refractory CD22-positive ALL.[10][Level of evidence B1]
Sources: 10 · Level of evidence B1
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Low-dose palliative radiation therapy may be considered in patients with symptomatic recurrence either within or outside the central nervous system.[11]
Sources: 11
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Patients with Ph-positive ALL are often taking imatinib at the time of relapse and thus have imatinib-resistant disease. Dasatinib is a novel tyrosine kinase inhibitor with efficacy against several different imatinib-resistant BCR::ABL1 fusion gene variants. Dasatinib has been approved for use in patients with Ph-positive ALL who are resistant to, or intolerant of, imatinib. The approval was based on a series of trials involving patients with chronic myeloid leukemia, one of which included small numbers of patients with lymphoid blast crisis or Ph-positive ALL.
Evidence (dasatinib):
In one study, ten patients were treated with dose-escalated dasatinib.[12] Seven of these patients had a complete hematologic response (<5% marrow blasts with normal peripheral blood cell counts), three of whom had a complete cytogenetic response.
Sources: 12
In one study, ten patients were treated with dose-escalated dasatinib.[12] Seven of these patients had a complete hematologic response (<5% marrow blasts with normal peripheral blood cell counts), three of whom had a complete cytogenetic response.
The common toxicities were reversible myelosuppression (89%) and pleural effusions (21%).
Virtually all of these patients relapsed within 6 months of the start of treatment with dasatinib.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025. Captured 2026-09-09.
Revumenib is an oral menin inhibitor that is approved by the FDA for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients aged 1 year and older.
In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[13]
Sources: AUGMENT-101 · 13
In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[13]
The overall rate of complete remission (CR) plus CRh (complete remission with partial hematologic recovery) was 21.2% (95% CI, 13.8%–30.3%). The median duration of CR plus CRh was 6.4 months (95% CI, 2.7–not reached).[13][Level of evidence C3]
Sources: 13 · Level of evidence C3
Of the 83 patients who were dependent on red blood cell and/or platelet transfusions, 14% became independent of transfusions during a 56-day postbaseline period.
Revumenib has a boxed warning for differentiation syndrome, which was observed in 29% of patients. Grade 3 or 4 differentiation syndrome was observed in 13% of patients, and one patient died (0.7%).
Sources: boxed warning
Grade 3 or higher QTc prolongation was observed in 12% of patients.
Because revumenib is metabolized by CYP3A4, the dose must be reduced in patients receiving strong CYP3A4 inhibitors. The standard dose for patients who weigh more than 40 kg is 270 mg orally twice daily, with a dose reduction to 160 mg orally twice daily for patients receiving a strong CYP3A4 inhibitor. Furthermore, the dose is adjusted according to body surface area in patients who weigh less than 40 kg.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
ALL is caused by certain changes to the way blood stem cells function, especially how they grow and divide into new cells. A risk factor is anything that increases the chance of getting a disease. Some risk factors for cancer, like smoking, can be changed. However, risk factors also include things people cannot change, like their genetics, getting older, and their health history.
There are many risk factors for ALL, but many do not directly cause cancer. Instead, they increase the chance of DNA damage in cells that may lead to ALL. Learn more about how cancer develops at What Is Cancer?
Sources: DNA · What Is Cancer?
Having one or more of these risk factors does not mean that you will get ALL. Many people with risk factors never develop ALL, while others with no known risk factors do.
Possible risk factors for ALL include:
being male
being White
being older than 70
past treatment with chemotherapy or radiation therapy
Sources: chemotherapy · radiation therapy
being exposed to high levels of radiation in the environment (such as nuclear radiation)
Sources: radiation
having certain genetic disorders, such as Down syndrome
Sources: genetic · Down syndrome
Talk with your doctor if you think you may be at risk.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The prognosis and treatment options for ALL depend on:
Sources: prognosis
the person's age
whether the cancer has spread to the brain or spinal cord
whether there are certain changes in the genes, including the Philadelphia chromosome
Sources: genes
whether the cancer has been treated before or has recurred (come back)
Sources: recurred
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
There are different types of treatment for patients with acute lymphoblastic leukemia (ALL).
The treatment of ALL usually has two phases.
The following types of treatment are used:
The following types of treatment are used:
Chemotherapy
Radiation therapy
Chemotherapy with stem cell transplant
Targeted therapy
Immunotherapy
New types of treatment are being tested in clinical trials.
Treatment for ALL may cause side effects.
Follow-up care may be needed.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Different types of treatment are available for people with ALL. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as whether the ALL is untreated, in remission, or recurrent, and your overall health and preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. Learn more at Questions to Ask Your Doctor About Treatment.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
There are two treatment phases of ALL:
Sources: ALL
Remission induction therapy is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission.
Sources: leukemia cells · bone marrow · remission
Consolidation therapy is the second phase of treatment. It begins once the leukemia is in remission. The goal of consolidation therapy is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse. This phase is also called remission continuation therapy.
Sources: relapse
Treatment called central nervous system (CNS) prophylaxis is usually given during each phase of therapy. Because standard doses of chemotherapy may not reach leukemia cells in the CNS (brain and spinal cord), the leukemia cells are able to hide in the CNS. Systemic chemotherapy given in high doses, intrathecal chemotherapy, and radiation therapy to the brain are able to reach leukemia cells in the CNS. These treatments are given to kill the leukemia cells and lessen the chance the leukemia will recur (come back).
Sources: central nervous system (CNS) prophylaxis · CNS · spinal cord · Systemic chemotherapy · intrathecal chemotherapy · radiation therapy
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. The way the chemotherapy is given depends on whether the leukemia cells have spread to the central nervous system (CNS; brain and spinal cord).
Systemic chemotherapy is when chemotherapy drugs are taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.
Sources: injected
Intrathecal chemotherapy may be used to treat ALL that has spread, or may spread, to the brain and spinal cord. Intrathecal chemotherapy is a method of placing chemotherapy directly into the cerebrospinal fluid, which is the fluid that surrounds the brain and spinal cord. When used to lessen the chance leukemia cells will spread to the brain and spinal cord, it is called CNS prophylaxis.
Learn more about Drugs Approved for Acute Lymphoblastic Leukemia.
Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People with Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People with Cancer
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: x-rays · radiation · External radiation therapy
External radiation therapy may be used to treat ALL that has spread, or may spread, to the brain and spinal cord. When used this way, it is called central nervous system (CNS) sanctuary therapy or CNS prophylaxis. Total-body irradiation may be used to send radiation toward the whole body when preparing for a stem cell transplant. External radiation therapy may also be used as palliative therapy to relieve symptoms and improve quality of life.
Sources: Total-body irradiation · stem cell transplant · palliative therapy · symptoms · quality of life
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Chemotherapy is given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy or total-body radiation therapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: Stem cells · donor · infusion
Learn more about Stem Cell Transplants in Cancer Treatment.
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
Targeted therapies used to treat ALL include:
dasatinib
Sources: dasatinib
imatinib mesylate
Sources: imatinib mesylate
inotuzumab ozogamicin
Sources: inotuzumab ozogamicin
nilotinib
Sources: nilotinib
revumenib
Sources: revumenib
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Immunotherapy helps a person's immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Immunotherapies used to treat ALL include:
blinatumomab
Sources: blinatumomab
inotuzumab ozogamicin
Sources: inotuzumab ozogamicin
CAR T-cell therapy with brexucabtagene autoleucel or tisagenlecleucel
Sources: CAR T-cell therapy · brexucabtagene autoleucel · tisagenlecleucel
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of treatment for ALL may include the risk of second cancers (new types of cancer). Regular follow-up exams are very important for long-term survivors.
Sources: late effects · second cancers · follow-up · survivors
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of ALL during the remission induction phase includes:
Sources: remission induction
combination chemotherapy
Sources: combination chemotherapy
targeted therapy with imatinib, in certain patients, some of whom will also have combination chemotherapy
Sources: targeted therapy · imatinib
supportive care including antibiotics and red blood cell and platelet transfusions
Sources: supportive care · antibiotics · transfusions
central nervous system (CNS) prophylaxis including chemotherapy (intrathecal and/or systemic) with or without radiation therapy to the brain
Sources: central nervous system (CNS) prophylaxis · intrathecal · systemic · radiation therapy
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of ALL during the post-remission phase includes:
Sources: post-remission
chemotherapy
Sources: chemotherapy
targeted therapy with dasatinib, imatinib, or nilotinib
Sources: targeted therapy · dasatinib · imatinib · nilotinib
chemotherapy with stem cell transplant
Sources: stem cell transplant
central nervous system (CNS prophylaxis) including chemotherapy (intrathecal and/or systemic) with or without radiation therapy to the brain
Sources: central nervous system (CNS prophylaxis) · intrathecal · systemic · radiation therapy
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of recurrent ALL may include:
Sources: recurrent
combination chemotherapy followed by stem cell transplant
Sources: combination chemotherapy · stem cell transplant
immunotherapy (blinatumomab or inotuzumab ozogamicin) followed by stem cell transplant
Sources: immunotherapy · blinatumomab · inotuzumab ozogamicin
low-dose radiation therapy as palliative care to relieve symptoms and improve quality of life
Sources: low-dose radiation therapy · palliative care · symptoms · quality of life
targeted therapy with dasatinib or revumenib for certain patients
Sources: targeted therapy · dasatinib · revumenib
CAR T-cell therapy (brexucabtagene autoleucel or tisagenlecleucel) for certain patients
Sources: CAR T-cell therapy · brexucabtagene autoleucel · tisagenlecleucel
Some of the treatments being studied in clinical trials for recurrent ALL include stem cell transplant using the patient's stem cells.
Sources: clinical trials · stem cells
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Leukemia, Lymphoma
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordB-cell Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia
ClinicalTrials.gov recordRelapsed/Refractory Philadelphia Positive B-precursor ALL
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
ClinicalTrials.gov recordRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordRecurrent B Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
ClinicalTrials.gov recordRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hodgkin or Non-Hodgkin...
ClinicalTrials.gov recordAIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC,...
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
ClinicalTrials.gov recordCytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia
Treatment of Untreated ALL
1 INDICATIONS AND USAGE ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded...
ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose...
Relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic leukemia following at least 2 chemotherapy regimens
1 INDICATION AND USAGE AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older .
Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Treatment of pediatric patients 1 to 21 yrs old with relapsed or refractory acute lymphocytic leukemia (ALL) after at least 2 prior regimens
• for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma,...
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
1.1 Neoplastic Disease JYLAMVO is indicated for the: treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. treatment of adults with mycosis...
1.1 Pediatric and Young Adult Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia KYMRIAH is indicated for treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or...
1.3 Autologous Peripheral Blood Progenitor Cell and Bone Marrow Transplantation LEUKINE is indicated for the acceleration of myeloid reconstitution following autologous peripheral blood progenitor cell (PBPC) or bone marrow...
1.1 Acute Lymphoblastic Leukemia Mercaptopurine tablets are indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.
• The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen.
1.1 First Line Acute Lymphoblastic Leukemia (ALL) ONCASPAR ® is indicated as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of pediatric and adult patients with ALL.
1 INDICATIONS AND USAGE PURIXAN is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.( 1.1 )
Treatment of Recurrent ALL
1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
1.1 Acute Lymphoblastic Leukemia XATMEP is indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen.
ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed...
DailyMed labelARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed...
DailyMed labelASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. ( 1.1 ) 1.1...
DailyMed label1 INDICATION AND USAGE AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). AUCATZYL is a CD19-directed genetically modified autologous T cell immunotherapy...
DailyMed label1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed...
DailyMed labelBLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second...
DailyMed labelINDICATIONS AND USAGE Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission...
DailyMed labelKYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or...
DailyMed label1 INDICATIONS & USAGE Mercaptopurine tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen....
DailyMed labelMERCAPTOPURINE is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 ) 1.1 Acute Lymphoblastic Leukemia...
DailyMed labelMethotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination...
DailyMed labelMethotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination...
DailyMed labelMethotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination...
DailyMed labelONCASPAR is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with: First-line acute lymphoblastic leukemia ( 1.1 ) Acute lymphoblastic...
DailyMed labelPURIXAN is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.( 1.1 ) 1.1 Acute Lymphoblastic Leukemia PURIXAN is...
DailyMed labelRYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed...
DailyMed labelTECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell...
DailyMed label